localized to the liver without any extrahepatic disease for at least six months after therapy. [1] PHL comprises 0.4% of all extra nodal non-Hodgkin's lymphomas, and between 1981 and February 2003, only 251 cases of PHL were reported in the literature. [2] Our patient was initially diagnosed to have liver abscesses. Although amoebic liver abscess is the predominant cause of liver abscess in India, hepatocellular carcinoma with necrosis and metastatic colonic cancer with central necrosis need consideration in the differential diagnosis. Only one case of PHL mimicking liver abscess [3] has been reported earlier. Lymphomas may cause portal venous obstruction either by direct infiltration, extrinsic compression at the porta by lymph nodes, tumor thrombus of the portal vein or by a hypercoagulable state. Direct portal infiltration was probably the cause in the present case. PHL causing portal venous obstruction has not been reported, although tumor thrombus in the portal vein has been described in patients with secondary lymphoma. [4] The type of PHL reported most commonly is diffuse large cell lymphoma (DLCL) of the B-cell phenotype. Our patient had a very rare variant known as ALCL of the T-cell phenotype. In a series of 31 patients with PHL, only one patient had ALCL. ALCL strongly expresses CD-30 (Ki-1) antigen; most are positive for the anaplastic lymphoma kinase (ALK) protein and have a characteristic translocation t(2;5). In the present case CD-30 was positive, but ALK staining was not available. Increased prevalence of hepatitis C virus (HCV) seropositivity has been reported in patients with PHL ranging from 21 -60%, [5] but our case was negative for anti-HCV.
In conclusion, this report represents a rare case of primary hepatic anaplastic large-cell lymphoma. Atypical liver masses or abscesses should raise the suspicion of lymphoma as one of the differential diagnoses. A case of leiomyosarcoma of kidney clinically and radiologically misdiagnosed as renal cell carcinoma Sir Renal sarcomas are rare, but highly aggressive neoplasms, accounting for 1 to 2% of all malignant renal tumors. [1] Since the prognosis for a renal sarcoma is particularly poor, differentiation from sarcomatoid renal cell carcinoma is necessary, but often difficult, based only on clinical presentation, radiographic findings, and, in some cases, pathological analysis. Leiomyosarcoma is the most common histological subtype constituting 50-60% of renal sarcomas. [1, 2] A 65-year-old female presented with an abdominal lump associated with pain, constipation, weight loss, and anorexia, of one-year duration. An ultrasound (US) of the abdomen revealed a large heterogeneous mass in the right lumbar region of the renal fossa measuring 14 x 10 cms. Doppler US showed a large thrombus in the inferior vena cava (IVC) up to the lower level of the hepatic veins. A computed tomography (CT) scan of the abdomen revealed a large exophytic, heterogeneous mass, with foci of necrosis, at the apex and midpolar region of the right kidney [ Figure 1 ]. A CT scan of the chest was unremarkable. A clinical diagnosis of renal cell carcinoma was made and the patient underwent radical nephrectomy. Thrombolytic therapy (streptokinase) was delivered through a catheter and patient was given heparin for ten days postoperatively. Grossly the tumor was large, globular, and encapsulated, measuring 15 x 11 x 8 cms at the upper pole of the right kidney.
The cut surface was a homogenous gray white, firm, with areas of whorling and trabeculations, along with foci of necrosis. The attached kidney measured 6 x 4 x 3 cm. The adrenal gland was unremarkable. The examined microsections showed a tumor composed of spindle cells arranged in interlacing fascicles with moderate nuclear pleomorphism, multinucleation, and focal areas of necrosis. Mitotic figures were 4-5 / 10 hpf [ Figure 2 ]. Van Gieson`s and Masson`s trichrome stains helped to confirm the smooth muscle origin. On immunohistochemistry, the tumor was vimentin and smooth muscle actin (SMA) positive, and cytokeratin (CK) and desmin negative. Therefore, a final diagnosis of renal leiomyosarcoma was established. Sections from the renal pelvis, ureter, and attached adrenal were unremarkable. Seven aortocaval lymph nodes showed reactive hyperplasia. Postoperative Doppler US revealed a thickened and narrowed inferior vena cava with a normal left renal vein. The patient was closely followed for one year, but thereafter was lost to follow-up.
Primary renal sarcomas constitute 0.8 to 2.7% of all renal tumors in adults. [3] Leiomyosarcomas constitute 0.12% of all invasive renal malignancies, as studied by Kendal. [4] Renal leiomyosarcoma has a preponderance in women, with gradually increasing incidence with advancing age. The patients present with a classical triad of flank pain, hematuria, and abdominal mass mimicking renal cell carcinoma. It is difficult to differentiate between leiomyosarcoma and renal cell carcinoma radiologically, and the diagnosis is usually made postoperatively. Histogenesis remains obscure, because renal sarcomas may arise from the smooth muscle fibers of the renal parenchyma, capsule, renal pelvis or vessels. Renal leiomyosarcoma, like many sarcomas, tends to displace rather than invade the parenchyma, and it is characterized by a rapid growth rate, frequent metastasis, and high local and systemic recurrence rates. Radical surgery offers the best chance of cure, and the role of adjuvant chemotherapy and / or radiotherapy remains debatable, due to the paucity of data on the treatment of this rare renal neoplasm. In a study by Kendal WS, leiomyosarcoma exhibited a median overall survival of 25 months, with a 25% five-year overall survival and a 60% five-year cause-specific survival. [4] Different etiologic factors, such as, local problems, malignancies, and lupus anticoagulants seem to contribute to the risk 
Marine life: New hope for cancer drugs
Sir The world's ocean covers 99 percent of the living space, that is, a total of 71 percent of the earth's surface. Life, most likely, first evolved in the sea, but our contact with most ocean life is very recent. Nowadays, this unfamiliar environment plays an important role in drug discovery programs. The chemical diversity of the marine ecosystem, starting from simple linear peptides to complex macrocyclic polyethers, draws us toward the discovery of new marine natural products (MNPs) in various therapeutic areas like cancer, inflammation, microbial infections, and various other deadly diseases. [1] Cancer is the biggest challenge for the current century, where marine organisms show a new hope to fight of IVC thrombosis. Retroperitoneal leiomyosarcoma, adrenal cortical carcinoma, and renal angiomyolipoma have all been reported as presenting in association with IVC thrombus, either due to direct compression or vascular invasion. Medical management includes the anticoagulation therapy -heparin, warfarin, and thrombolytic agents, while surgical therapy encompasses caval interruption and thrombectomy. against these dangerous diseases. Interestingly after tunicate cyclodepsipeptide 'Didemnin', the first marine compound, entered human clinical trials in the US for the treatment of cancer, several marine compounds like Sponge Polyketide 'Calyculin A' (a selective inhibitor of protein phosphatase 1) isolated from Discodermia calyx; 'Bryostatin 1' a Macrocyclic lactone isolated from bryozoan sp. Bugula neritina; tunicate compounds including cyclic peptide 'Vitilevuamide' and 'Diazonamide', cyclic depsipeptides 'Dehydrodidemnin B (Aplidine) and Didemnin B', and tetrahydroisoquinolone alkaloid 'Ecteinascidin 743', respectively, isolated from Didemnin cucliferum, Diazona angulata, Trididemnum solidum, and Ecteinascidia turbinate have entered clinical trials. [2] Ascididemnin, Cryptophycins, Curacin A, CGX-1160, CGX-1007dictyodendrins, Dolastatin-10, Discodermolide, Eleutherobin, E7389, Girolline, GTS-21, HTI-286, ILX 651, IPL-576, Kahalalide F, KRN-7000, Laulimalide, Manoalide, Peloruside A, Spisulosine, Soblidotin, Squalamine, Sarcodictyin, salicylihalimides A, and Thiocoraline are a few more marine anticancer compounds in the long-term clinical study. [3, 4] Presently, the Ara-C compound, isolated from the sponge Cryptotheca crypta has reached the market and is used with other anticancer drugs in the treatment of acute myelocytic leukemia (AML) and lymphomas, while antiviral Ara-A is another marine compound in the market.
Information on marine sources is very scarce, thus, an in-depth study of marine life will surely decipher the sustainable exploitation of this environment for human healthcare. Marine resource is immeasurable and extraordinary for the discovery of new anticancer drugs; therefore, a more rigorous study is needed to explore MNPs. Rapid advances and recent researches on the mechanisms responsible for the neoplastic disease have resulted in the identification of novel molecular targets. These new targets broaden the scope for antitumor marine natural product research. Moreover, modern molecular mechanism-based screening methods add immensely to drug discovery programs.
Nowadays, for their therapeutic potential, marine organisms are getting great recognition for their importance to human life. However, the fact cannot be denied that growing barriers like lack of versatile infrastructure and global cooperation between clinical and basic research, along with the ever increasing complexities involved in conducting clinical research, are making it more difficult to translate new knowledge into practical applications. Hence, more concentration is required for the study and research of MNPs. This
